A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
Public ClinicalTrials.gov record NCT04658186. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants diagnosed with early-stage Parkinson's Disease.
Study identification
- NCT ID
- NCT04658186
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 496 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2020
- Primary completion
- Sep 5, 2024
- Completion
- Sep 5, 2024
- Last update posted
- Oct 30, 2025
2020 – 2024
United States locations
- U.S. sites
- 57
- U.S. states
- 31
- U.S. cities
- 50
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pd0053 50140 | Birmingham | Alabama | 35233 | — |
| Pd0053 50506 | Phoenix | Arizona | 85004-1150 | — |
| Pd0053 50081 | Phoenix | Arizona | 85013 | — |
| Pd0053 50391 | Tucson | Arizona | 85710 | — |
| Pd0053 50539 | Little Rock | Arkansas | 72205 | — |
| Pd0053 50519 | Fountain Valley | California | 92708 | — |
| Pd0053 50385 | Fresno | California | 93710 | — |
| Pd0053 50416 | La Jolla | California | 92037 | — |
| Pd0053 50118 | Los Angeles | California | 90033-5315 | — |
| Pd0053 50531 | Englewood | Colorado | 80113 | — |
| Pd0053 50392 | Danbury | Connecticut | 06810 | — |
| Pd0053 50538 | Farmington | Connecticut | 06030 | — |
| Pd0053 50396 | Boca Raton | Florida | 33486 | — |
| Pd0053 50524 | Bradenton | Florida | 34205 | — |
| Pd0053 50199 | Miami | Florida | 33136 | — |
| Pd0053 50394 | Tampa | Florida | 33613 | — |
| Pd0053 50544 | Augusta | Georgia | 30912-0004 | — |
| Pd0053 50401 | Chicago | Illinois | 60611 | — |
| Pd0053 50310 | Chicago | Illinois | 60612-3863 | — |
| Pd0053 50399 | Winfield | Illinois | 60190 | — |
| Pd0053 50549 | Iowa City | Iowa | 52242 | — |
| Pd0053 50074 | Kansas City | Kansas | 66160 | — |
| Pd0053 50121 | Lexington | Kentucky | 40536-0284 | — |
| Pd0053 50395 | New Orleans | Louisiana | 70121 | — |
| Pd0053 50529 | Baltimore | Maryland | 21201-1606 | — |
| Pd0053 50547 | Baltimore | Maryland | 21287 | — |
| Pd0053 50243 | Boston | Massachusetts | 02114 | — |
| Pd0053 50546 | Worcester | Massachusetts | 01655 | — |
| Pd0053 50386 | Farmington Hills | Michigan | 48334 | — |
| Pd0053 50536 | Saint Paul | Minnesota | 55130 | — |
| Pd0053 50397 | Las Vegas | Nevada | 89104 | — |
| Pd0053 50299 | New Brunswick | New Jersey | 08903 | — |
| Pd0053 50077 | New York | New York | 10021 | — |
| Pd0053 50521 | New York | New York | 10029 | — |
| Pd0053 50119 | New York | New York | 10032 | — |
| Pd0053 50530 | Stony Brook | New York | 11794 | — |
| Pd0053 50535 | Williamsville | New York | 14221 | — |
| Pd0053 50372 | Cleveland | Ohio | 44106 | — |
| Pd0053 50311 | Cleveland | Ohio | 44195 | — |
| Pd0053 50255 | Columbus | Ohio | 43210 | — |
| Pd0053 50527 | Toledo | Ohio | 43606 | — |
| Pd0053 50398 | Tulsa | Oklahoma | 74136 | — |
| Pd0053 50510 | Portland | Oregon | 97239 | — |
| Pd0053 50526 | Philadelphia | Pennsylvania | 19107 | — |
| Pd0053 50084 | Charleston | South Carolina | 29425 | — |
| Pd0053 50532 | Knoxville | Tennessee | 37920 | — |
| Pd0053 50543 | Memphis | Tennessee | 38157 | — |
| Pd0053 50525 | Houston | Texas | 77030-5301 | — |
| Pd0053 50113 | Houston | Texas | 77030 | — |
| Pd0053 50400 | San Antonio | Texas | 78229 | — |
| Pd0053 50107 | Burlington | Vermont | 05401-1473 | — |
| Pd0053 50542 | Charlottesville | Virginia | 22908 | — |
| Pd0053 50410 | Fairfax | Virginia | 22031 | — |
| Pd0053 50534 | Virginia Beach | Virginia | 23456 | — |
| Pd0053 50292 | Kirkland | Washington | 98034-3030 | — |
| Pd0053 50419 | Spokane | Washington | 99202 | — |
| Pd0053 50402 | Crab Orchard | West Virginia | 25827 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04658186, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2025 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04658186 live on ClinicalTrials.gov.